Symbols / NVCR Stock $13.61 -4.69% NovoCure Limited

Healthcare • Medical Devices • Switzerland • NMS
NVCR (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Medical Devices
CEO Mr. Frank Leonard
Exch · Country NMS · Switzerland
Market Cap 1.58B
Enterprise Value 1.46B
Income -173.05M
Sales 674.41M
FCF (ttm) 5.08M
Book/sh 2.85
Cash/sh 3.73
Employees 1,605
Insider 10d —
IPO Oct 01, 2015
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -11.41
PEG —
P/S 2.34
P/B 4.77
P/C —
EV/EBITDA -8.77
EV/Sales 2.16
Quick Ratio 2.66
Current Ratio 2.90
Debt/Eq 71.04
LT Debt/Eq —
EPS (ttm) -1.53
EPS next Y -1.19
EPS Growth —
Revenue Growth 12.30%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-07-23
Earnings (prior) 2026-04-30
ROA -11.06%
ROE -49.96%
ROIC —
Gross Margin 75.45%
Oper. Margin -38.73%
Profit Margin -25.66%
Shs Outstand 115.82M
Shs Float 95.25M
Insider Own 10.01%
Instit Own 88.35%
Short Float 10.70%
Short Ratio 4.66
Short Interest 9.15M
52W High 18.92
vs 52W High -28.07%
52W Low 9.82
vs 52W Low 38.59%
Beta 0.92
Impl. Vol. 57.72%
Rel Volume 1.21
Avg Volume 1.58M
Volume 1.92M
Target (mean) $26.00
Tgt Median $27.00
Tgt Low $17.00
Tgt High $46.00
# Analysts 7
Recom Buy
Prev Close $14.28
Price $13.61
Change -4.69%
About

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$26.00
Mean price target
2. Current target
$13.61
Latest analyst target
3. DCF / Fair value
$0.79
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$13.61
Low
$17.00
High
$46.00
Mean
$26.00

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-06-18 reit HC Wainwright & Co. Buy → Buy $46
2026-05-04 main Wells Fargo Equal-Weight → Equal-Weight $17
2026-05-01 main Evercore ISI Group Outperform → Outperform $20
2026-04-16 reit Wedbush Neutral → Neutral $18
2026-02-26 main HC Wainwright & Co. Buy → Buy $49
2026-02-12 main HC Wainwright & Co. Buy → Buy $47
2026-01-15 reit Wedbush Neutral → Neutral $18
2026-01-13 main HC Wainwright & Co. Buy → Buy $39
2025-10-30 main HC Wainwright & Co. Buy → Buy $42
2025-10-27 main JP Morgan Neutral → Neutral $23
2025-07-25 down Wells Fargo Overweight → Equal-Weight $15
2025-07-08 init Ladenburg Thalmann — → Buy $30
2025-06-27 reit Piper Sandler Overweight → Overweight $34
2025-04-23 main Piper Sandler Overweight → Overweight $34
2025-04-16 main Wedbush Neutral → Neutral $27
2025-04-10 main JP Morgan Neutral → Neutral $28
2025-01-14 reit HC Wainwright & Co. Buy → Buy $38
2024-12-13 main Piper Sandler Overweight → Overweight $42
2024-12-03 main HC Wainwright & Co. Buy → Buy $38
2024-12-02 reit HC Wainwright & Co. Buy → Buy $38
News
RSS: Latest NVCR news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-06-04 LEONARD FRANCIS XAVIER II Chief Executive Officer — 34,273 $17.93 $614,635
2026-06-03 HILLEMAN JERYL L Director — 11,610 $0.00 $0
2026-06-03 LEUNG KINYIP GABRIEL Director — 11,610 $0.00 $0
2026-06-03 HUNG DAVID T Director — 11,610 $0.00 $0
2026-06-03 VERNON WILLIAM ANTHONY Director — 11,610 $0.00 $0
2026-06-03 SCANNELL TIMOTHY J. Director — 11,610 $0.00 $0
2026-06-03 MADDEN MARTIN J Director — 11,610 $0.00 $0
2026-06-03 OCEAN ALLYSON J Director — 11,610 $0.00 $0
2026-06-03 STAFFORD KRISTIN Director — 11,610 $0.00 $0
2026-06-02 HILLEMAN JERYL L Director — 2,945 $15.77 $46,445
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
655.35
+8.28%
605.22
+18.82%
509.34
-5.30%
537.84
Operating Revenue
655.35
+8.28%
605.22
+18.82%
509.34
-5.30%
537.84
Cost Of Revenue
166.88
+21.65%
137.18
+6.94%
128.28
+11.68%
114.87
Reconciled Cost Of Revenue
166.88
+21.65%
137.18
+6.94%
128.28
+11.68%
114.87
Gross Profit
488.47
+4.37%
468.04
+22.83%
381.06
-9.91%
422.97
Operating Expense
642.27
+0.59%
638.53
+4.01%
613.93
+19.79%
512.50
Research And Development
224.54
+7.11%
209.65
-6.01%
223.06
+8.24%
206.09
Selling General And Administration
417.73
-2.60%
428.89
+9.73%
390.87
+27.56%
306.41
Selling And Marketing Expense
240.06
+0.42%
239.06
+5.40%
226.81
+30.61%
173.66
General And Administrative Expense
177.67
-6.41%
189.83
+15.71%
164.06
+23.58%
132.75
Other Gand A
177.67
-6.41%
189.83
+15.71%
164.06
+23.58%
132.75
Total Expenses
809.15
+4.31%
775.72
+4.51%
742.21
+18.31%
627.36
Operating Income
-153.80
+9.79%
-170.50
+26.78%
-232.87
-160.12%
-89.52
Total Operating Income As Reported
-153.80
+9.79%
-170.50
+26.78%
-232.87
-160.12%
-89.52
EBITDA
-104.56
+4.58%
-109.58
+38.25%
-177.45
-161.39%
-67.89
Normalized EBITDA
-100.24
+7.92%
-108.87
+38.37%
-176.66
-174.46%
-64.36
Reconciled Depreciation
14.65
+30.40%
11.23
+2.43%
10.97
+3.25%
10.62
EBIT
-119.21
+1.33%
-120.82
+35.88%
-188.42
-139.99%
-78.51
Total Unusual Items
-4.32
-502.79%
-0.72
+10.04%
-0.80
+77.38%
-3.52
Total Unusual Items Excluding Goodwill
-4.32
-502.79%
-0.72
+10.04%
-0.80
+77.38%
-3.52
Net Income
-136.23
+19.21%
-168.63
+18.55%
-207.04
-123.75%
-92.53
Pretax Income
-136.25
-3.88%
-131.16
+31.59%
-191.74
-134.27%
-81.85
Net Non Operating Interest Income Expense
21.87
-45.39%
40.05
-4.47%
41.93
+274.35%
11.20
Interest Expense Non Operating
17.04
+64.72%
10.34
+211.63%
3.32
-0.45%
3.33
Net Interest Income
21.87
-45.39%
40.05
-4.47%
41.93
+274.35%
11.20
Interest Expense
17.04
+64.72%
10.34
+211.63%
3.32
-0.45%
3.33
Interest Income Non Operating
12.87
-43.35%
22.72
+15.71%
19.64
+79.17%
10.96
Interest Income
12.87
-43.35%
22.72
+15.71%
19.64
+79.17%
10.96
Other Income Expense
-4.32
-502.79%
-0.72
+10.04%
-0.80
+77.38%
-3.52
Gain On Sale Of Security
-4.32
-502.79%
-0.72
+10.04%
-0.80
+77.38%
-3.52
Tax Provision
-0.02
-100.06%
37.47
+144.82%
15.30
+43.18%
10.69
Tax Rate For Calcs
0.00
-99.90%
0.00
+0.00%
0.00
+0.00%
0.00
Tax Effect Of Unusual Items
-0.00
+99.43%
-0.15
+10.04%
-0.17
+77.38%
-0.74
Net Income Including Noncontrolling Interests
-136.23
+19.21%
-168.63
+18.55%
-207.04
-123.75%
-92.53
Net Income From Continuing Operation Net Minority Interest
-136.23
+19.21%
-168.63
+18.55%
-207.04
-123.75%
-92.53
Net Income From Continuing And Discontinued Operation
-136.23
+19.21%
-168.63
+18.55%
-207.04
-123.75%
-92.53
Net Income Continuous Operations
-136.23
+19.21%
-168.63
+18.55%
-207.04
-123.75%
-92.53
Normalized Income
-131.91
+21.51%
-168.06
+18.58%
-206.41
-129.98%
-89.75
Net Income Common Stockholders
-136.23
+19.21%
-168.63
+18.55%
-207.04
-123.75%
-92.53
Diluted EPS
-1.22
+21.79%
-1.56
+20.00%
-1.95
-121.59%
-0.88
Basic EPS
-1.22
+21.79%
-1.56
+20.00%
-1.95
-121.59%
-0.88
Basic Average Shares
111.47
+3.37%
107.83
+1.36%
106.39
+1.65%
104.66
Diluted Average Shares
111.47
+3.37%
107.83
+1.36%
106.39
+1.65%
104.66
Diluted NI Availto Com Stockholders
-136.23
+19.21%
-168.63
+18.55%
-207.04
-123.75%
-92.53
Total Other Finance Cost
-26.04
+5.91%
-27.67
-8.06%
-25.61
-616.68%
-3.57
Line Item Trend 2023-12-31
Total Assets
1,146.13
Current Assets
1,034.41
Cash Cash Equivalents And Short Term Investments
910.62
Cash And Cash Equivalents
240.82
Cash Equivalents
230.87
Cash Financial
9.96
Other Short Term Investments
669.79
Receivables
77.11
Accounts Receivable
61.22
Other Receivables
15.89
Inventory
38.15
Raw Materials
10.27
Work In Process
9.80
Finished Goods
18.09
Prepaid Assets
6.78
Restricted Cash
1.74
Total Non Current Assets
111.72
Net PPE
97.70
Gross PPE
152.51
Accumulated Depreciation
-54.81
Properties
0.00
Land And Improvements
24.70
Machinery Furniture Equipment
35.41
Other Properties
80.71
Leases
11.70
Other Non Current Assets
14.02
Total Liabilities Net Minority Interest
783.63
Current Liabilities
179.12
Payables And Accrued Expenses
154.57
Payables
94.39
Accounts Payable
94.39
Other Payable
—
Current Accrued Expenses
60.18
Employee Benefits
8.26
Current Debt And Capital Lease Obligation
8.32
Current Debt
—
Other Current Borrowings
—
Current Capital Lease Obligation
8.32
Current Deferred Liabilities
16.22
Current Deferred Revenue
16.22
Total Non Current Liabilities Net Minority Interest
604.52
Long Term Debt And Capital Lease Obligation
596.24
Long Term Debt
568.82
Long Term Capital Lease Obligation
27.42
Non Current Deferred Liabilities
0.00
Non Current Deferred Revenue
0.00
Other Non Current Liabilities
0.02
Stockholders Equity
362.50
Common Stock Equity
362.50
Capital Stock
0.00
Common Stock
0.00
Share Issued
107.08
Ordinary Shares Number
107.08
Treasury Shares Number
0.00
Additional Paid In Capital
1,353.47
Retained Earnings
-985.50
Gains Losses Not Affecting Retained Earnings
-5.47
Other Equity Adjustments
-5.47
Total Equity Gross Minority Interest
362.50
Total Capitalization
931.32
Working Capital
855.29
Invested Capital
931.32
Total Debt
604.56
Net Debt
328.00
Capital Lease Obligations
35.74
Net Tangible Assets
362.50
Tangible Book Value
362.50
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-49.03
-85.94%
-26.37
+64.04%
-73.34
-338.20%
30.79
Cash Flow From Continuing Operating Activities
-49.03
-85.94%
-26.37
+64.04%
-73.34
-338.20%
30.79
Net Income From Continuing Operations
-136.23
+19.21%
-168.63
+18.55%
-207.04
-123.75%
-92.53
Depreciation Amortization Depletion
14.65
+30.40%
11.23
+2.43%
10.97
+3.25%
10.62
Depreciation
13.13
+33.09%
9.87
+1.76%
9.70
—
Amortization Cash Flow
1.52
+10.96%
1.37
+7.46%
1.27
—
Depreciation And Amortization
14.65
+30.40%
11.23
+2.43%
10.97
+3.25%
10.62
Amortization Of Intangibles
1.52
+10.96%
1.37
+7.46%
1.27
—
Other Non Cash Items
4.95
+860.22%
-0.65
-585.26%
-0.10
+95.71%
-2.22
Stock Based Compensation
104.83
-34.49%
160.03
+38.43%
115.61
+8.09%
106.95
Asset Impairment Charge
4.85
+318.55%
1.16
+135.09%
0.49
-48.38%
0.95
Operating Gains Losses
1.25
+651.10%
-0.23
-240.99%
0.16
+104.94%
-3.26
Net Foreign Currency Exchange Gain Loss
1.25
+651.10%
-0.23
-240.99%
0.16
+104.94%
-3.26
Change In Working Capital
-20.07
-450.15%
-3.65
-112.30%
29.66
+151.40%
11.80
Change In Receivables
-38.94
-47.73%
-26.36
-189.61%
29.41
+1054.85%
2.55
Changes In Account Receivables
-38.94
-47.73%
-26.36
-189.61%
29.41
+1054.85%
2.55
Change In Inventory
-5.67
-320.72%
2.57
+128.79%
-8.92
-105.41%
-4.34
Change In Payables And Accrued Expense
18.96
-0.77%
19.11
+28.50%
14.87
+4.29%
14.26
Change In Other Current Assets
10.85
+46.68%
7.39
+81.61%
4.07
-42.70%
7.11
Change In Other Current Liabilities
-5.27
+17.08%
-6.36
+34.98%
-9.78
-25.83%
-7.77
Investing Cash Flow
437.28
+411.80%
-140.24
-176.16%
184.15
+231.57%
-139.96
Cash Flow From Continuing Investing Activities
437.28
+411.80%
-140.24
-176.16%
184.15
+231.57%
-139.96
Net PPE Purchase And Sale
-26.65
+37.82%
-42.85
-58.18%
-27.09
-26.85%
-21.36
Purchase Of PPE
-26.65
+37.82%
-42.85
-58.18%
-27.09
-26.85%
-21.36
Capital Expenditure
-26.65
+37.82%
-42.85
-58.18%
-27.09
-26.85%
-21.36
Net Investment Purchase And Sale
463.92
+576.37%
-97.39
-146.10%
211.24
+278.11%
-118.60
Purchase Of Investment
-821.08
+6.20%
-875.39
+12.79%
-1,003.74
+22.66%
-1,297.89
Sale Of Investment
1,285.00
+65.17%
778.00
-35.97%
1,214.98
+3.03%
1,179.29
Financing Cash Flow
-451.34
-599.74%
90.31
+472.08%
15.79
+1.91%
15.49
Cash Flow From Continuing Financing Activities
-451.34
-599.74%
90.31
+472.08%
15.79
+1.91%
15.49
Net Issuance Payments Of Debt
-460.97
-648.71%
84.01
+840190.00%
-0.01
+64.29%
-0.03
Issuance Of Debt
99.98
+3.15%
96.92
0.00
0.00
Repayment Of Debt
-560.95
-4244.03%
-12.91
-129030.00%
-0.01
+64.29%
-0.03
Long Term Debt Issuance
99.98
+3.15%
96.92
0.00
0.00
Long Term Debt Payments
-560.95
-4244.03%
-12.91
-129030.00%
-0.01
+64.29%
-0.03
Net Long Term Debt Issuance
-460.97
-648.71%
84.01
+840190.00%
-0.01
+64.29%
-0.03
Net Common Stock Issuance
3.66
-11.90%
4.15
-6.02%
4.42
-15.47%
5.22
Proceeds From Stock Option Exercised
6.11
+183.53%
2.16
-81.06%
11.38
+10.55%
10.29
Net Other Financing Charges
-0.15
—
—
—
Changes In Cash
-63.10
+17.30%
-76.30
-160.27%
126.60
+235.14%
-93.68
Effect Of Exchange Rate Changes
0.39
+326.44%
-0.17
-232.82%
0.13
+235.05%
-0.10
Beginning Cash Position
166.09
-31.53%
242.56
+109.41%
115.83
-44.74%
209.61
End Cash Position
103.39
-37.75%
166.09
-31.53%
242.56
+109.41%
115.83
Free Cash Flow
-75.68
-9.32%
-69.22
+31.07%
-100.43
-1164.99%
9.43
Interest Paid Supplemental Data
13.41
+73.79%
7.71
+128466.67%
0.01
-85.37%
0.04
Income Tax Paid Supplemental Data
30.67
+30.73%
23.46
+71.70%
13.66
+149.36%
5.48
Amortization Of Securities
-23.26
+9.29%
-25.64
-11.09%
-23.08
-1402.86%
-1.54
Common Stock Issuance
3.66
-11.90%
4.15
-6.02%
4.42
-15.47%
5.22
Issuance Of Capital Stock
3.66
-11.90%
4.15
-6.02%
4.42
-15.47%
5.22
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category